Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Drops By 39.9%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 49,784 shares, a decline of 39.9% from the June 30th total of 82,827 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average daily volume of 87,989 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. bought a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals at the end of the most recent quarter. 1.95% of the stock is owned by institutional investors.

Sonoma Pharmaceuticals Stock Performance

Shares of SNOA opened at $1.10 on Friday. The stock has a market cap of $5.27 million, a PE ratio of -0.58 and a beta of 1.27. Sonoma Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $6.92. The firm’s 50-day simple moving average is $1.16 and its two-hundred day simple moving average is $1.96.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%. The business had revenue of $5.56 million for the quarter, compared to the consensus estimate of $5.57 million.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.